7 completed, 3 terminated. 6 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow pradigastat: new trials by email Literature Review of pradigastat trials Research Report on pradigastat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof of Concept Study of Pradigastat in Patients With Functional Constipation Pradigastat Tablets 20mg, Pradigastat Tablets 40mg, Pradigastat Tablets 20mg matching Placebo - Functional Constipation | Phase 2 | Completed | Anji Pharma | 181 | 2020-09-22 | 2022-08-24 |
| Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients LCQ908, placebo - Non-alcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2013-06-01 | 2016-02-04 |
| Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome. LCQ908 - Familial Chylomicronemia Syndrome (FCS) (HLP Type I) | Phase 3 | Terminated | Novartis Pharmaceuticals | 38 | 2013-02-01 | 2016-11-15 |
| A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome LCQ908, Placebo - Familial Chylomicronemia Syndrome (FCS) | Phase 3 | Completed | Novartis Pharmaceuticals | 45 | 2012-07-01 | 2015-06-03 |
| A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia LCQ908, Fenofibrate, Fish Oil - Non Familial Chylocmicronemia Syndrome (Non-FCS) | Phase 2 | Completed | Novartis Pharmaceuticals | 58 | 2012-06-01 | 2020-12-17 |
| Pharmacokinetics of LCQ908 in Patients With Renal Impairment LCQ908 - Renal Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 58 | 2012-05-01 | 2020-12-19 |
| Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment LCQ908 - Hepatic Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 53 | 2012-04-01 | 2020-12-19 |
| Efficacy of LCQ908 on Cardiovascular Risk pradigastat (LCQ908), Placebo - Coronary Artery Disease, Hypertriglyceridemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 41 | 2011-12-01 | 2016-04-14 |
| A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients LCQ908, Placebo - Hepatitis C | Phase 2 | Terminated | Novartis Pharmaceuticals | 32 | 2011-07-01 | 2012-05-08 |
| Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia LCQ908, Placebo - Hyperlipoproteinemia | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 8 | 2010-05-01 | 2020-12-17 |
Hypertriglyceridemia (4) · Familial hyperchylomicronemia syndrome (2) · Hyperlipoproteinemias (2) · Coronary Artery Disease (1) · Hepatitis C (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type I (1) · Non-alcoholic Fatty Liver Disease (1) · Renal Insufficiency (1)
Novartis Pharmaceuticals (9) · Anji Pharma (1)
United States (8) · Canada (4) · France (2) · Germany (2) · Netherlands (2) · South Africa (2) · United Kingdom (2) · China (1) · New Zealand (1) · Russia (1) · Spain (1)
Dan Meyers, M.D. (1)